Differences in efficacy and safety of pharmaceutical treatments between men and women: An umbrella review

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Gartlehner, Gerald ^a,b   Chapman, Andrea ^a   Strobelberger, Michaela ^a   Thaler, Kylie ^a  

^a DANUBE UNIVERSITY KREMS   (Austria)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOLASETRON MESILATE; FLUOXETINE; FLUVOXAMINE; GRANISETRON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MEVINOLIN; ONDANSETRON; PAROXETINE; PLACEBO; VENLAFAXINE;

ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR DEPRESSION; NAUSEA; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; TREATMENT PLANNING; FEMALE; MALE; REVIEW;

DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; PAROXETINE; SEX FACTORS; TREATMENT OUTCOME;

EID: 77955605942     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011895     Document Type: Article

References (112)

1. National Institute of Health (1994) Guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register 59: 14508-14513.
2. Holdcroft A (2007) Gender bias in research: how does it affect evidence based medicine? J R Soc Med 100: 2-3.
3. Committee on Understanding the Biology of Sex and Gender Differences (2001) Exploring the Biological Contributions to Human Health: Does Sex Matter? In: Wizemann TM, Pardue M-L, eds. Washington, D.C.: National Academy Press.
4. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270: 2590-2597.
5. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ (1996) Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 94: 2535-2541.
6. Bardhan KD, Bodemar G, Geldof H, Schutz E, Heath A, et al. (2000) A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 14: 23-34.
7. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, et al. (2000) Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355: 1035-1040.
8. Lew KH, Ludwig EA, Milad MA, Donovan K, on E Jr., et al. (1993) Gender-based effects on methylprednisolone pharmacokinetics and pharma-codynamics. Clin Pharmacol Ther 54: 402-414.
9. Freedman RR, Girgis R (2000) Effects of menstrual cycle and race on peripheral vascular alpha-adrenergic responsiveness. Hypertension 35: 795-799.
10. Oregon Health & Science University (2001) History of DERP. Available: http://www.ohsu.edu/ohsuedu/research/policycenter/derp/derp-history. cfm. Accessed February 12, 2010.
11. Oregon Health & Science University (2001) Products. Available: www.ohsu. edu/ohsuedu/research/policycenter/DERP/products.cfm. Accessed February 12, 2010.
12. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, et al. (2004) Systems for grading the quality of evidence and the strength ofrecommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 4: 38.
13. IMSC. GRADEpro (2010) Available: http://www.ims.cochrane.org/revman/ gradepro. Accessed February 12, 2010.
14. Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, et al. (1998) Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 16: 1568-1573.
15. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, et al. (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol 13: 1242-1248.
16. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, et al. (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16: 754-760.
17. Spector JI, Lester EP, Chevlen EM, Sciortino D, Harvey JH, et al. (1998) A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy. Oncologist 3: 432-438.
18. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, et al. (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14: 2242-2249.
19. Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, et al. (1996) Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur JCancer 32A: 1523-1529.
20. Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, et al. (1996) A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur JCancer 32A: 807-813.
21. Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA273: 1450-1456.
22. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, et al. (2003)Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. JAm Coll Cardiol 41: 1529-1538.
23. Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl JMed 345: 1667-1675.
24. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 759-766.
25. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, etal. (2000)Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587.
26. Shekelle P, Morton S, Atkinson S, Suttorp M, Tu W, et al.(2003) Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness. Evid Rep Technol Assess (Summ). pp 1-6.
27. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, et al. (1992) Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J13: 28-32.
28. The Beta-Blocker Pooling Project Research Group (1988) The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J9: 8-16.
29. LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282: 2340-2346.
30. Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago A, et al. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288: 2411-2420.
31. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, et al. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl JMed 345: 494-502.
32. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, et al. (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358: 527-533.
33. Thase ME, Entsuah R, Cantillon M, Kornstein SG (2005) Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 14: 609-616.
34. Entsuah AR, Huang H, Thase ME (2001) Response and remission rates in different subpopulations with major depressive disorder administered venlafax-ine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 62: 869-877.
35. Kennedy SH, Fulton KA, Bagby RM, Greene AL, Cohen NL, et al. (2006) Sexual function during bupropion or paroxetine treatment ofmajor depressive disorder. Can JPsychiatry 51: 234-242.
36. Bradford RH, Downton M, Chremos AN, Langendorfer A, Stinnett S, et al. (1993) Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med 118: 850-855.
37. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, et al. (2008) Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 149: 734-750.
38. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, et al. (2008) Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 31: 851-865.
39. Rothwell PM (2005) Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365: 176-186.
40. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, et al. (2010) Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 121: 1069-1077.
41. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849-1860.
42. Ginsburg GS, Willard HF (2009) Genomic and personalized medicine: foundations and applications. Transl Res 154: 277-287.
43. Helfand M (2006) Drug Class Review on Newer Antihistamines. Final Report Update 1. Available: http://www.ohsu.edu/drugeffectiveness/reports/final. cfm. Accessed January 1, 2010.
44. Chou R, Helfand M, Carson S (2005) Drug Class Review on Angiotensin Converting Enzyme Inhibitors. Available: http://derp.ohsu.edu/about/final-products.cfm. Accessed January 1, 2010.
45. Furmaga E, Glassman P, Rhodes S, Suttorp M, Mojica W (2006) Drug Class Review on Drug Class Review on Angiotensin II Receptor Antagonists. Available: http://derp.ohsu.edu/about/final-products.cfm. Accessed January 1, 2010.
46. Gartlehner G, Morgan LC, Thieda P, Thaler K, Hansen RA, et al. (2008) Drug class review: Second generation antidepressants. Update 2. Available: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
47. McDonagh M, Peterson K, N NL, Thakurta S (2008) Drug class review: Antiepileptic drugs for indications other than epilepsy. Update 2. Available: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
48. Peterson K, McDonagh MS, Carson S, Thakurta S (2009) Drug class review: Newer antiemetics. Update 1. Available: http://www.ohsu.edu/drugeffective-ness/reports/final.cfm. Accessed January 1, 2010.
49. Dailey JH, Glassman P, McDonagh M, Peterson K, Suttorp M, et al. (2007) Drug Class Review on Antiplatelets. Available: http://www.ohsu.edu/ drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
50. McDonagh MS, Peterson K, Carson S, Chan B, Thakurta S (2008) Drug class review on atypical antipsychotic drugs. Update #2 final report. Available: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
51. Jonas DE, Kiser K, Shilliday BB, Morgan LC, Thieda P, et al. (2008) Drug class review: Controller medications for asthma. Available: http://derp.ohsu. edu/final/Asthma_final%20report.pdf. Accessed January 1, 2010.
52. Norris S, McNally T, Thakurta S (2008) Drug class review: Quick-relief medications for asthma. Available: http://www.ohsu.edu/drugeffectiveness/ reports/final.cfm. Accessed January 1, 2010.
53. McDonagh MS, Christensen V, Peterson K, Thakurta S (2009) Drug Class Review on Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder. Available: http://www.ohsu.edu/drugeffectiveness/reports/final. cfm. Accessed January 1, 2010.
54. Helfand M, Peterson K, Christensen V, Dana T, Thakurta S (2009) Drug class review: Beta adrenergic blockers. Update 4. Available: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
55. Norris SL, Yen P, Dana TL, Care BR, Burda BU (2006) Drug Class Review on Beta2-Agonists. Final Report. Available: http://derp.ohsu.edu/final/BA_final_ report_orginal.pdf. Accessed January 1, 2010.
56. McDonagh SM, Eden KB, Peterson K (2005) Drug Class Review on Calcium Channel Blockers. Final Report. Available: http://derp.ohsu.edu/final/ CCB_%20Final_Report_update%202.pdf. Accessed January 1, 2010.
57. Gartlehner G, Jonas DE, Morgan LC, Ringel Y, Hansen RA, et al. (2007) Drug Class Review on Constipation Drugs. Available: http://www.ohsu.edu/ drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
58. Chou R, Helfand M, Peterson K, Dana T (2004) Drug Class Review of Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDS). Available:. http://www.ohsu.edu/drugeffectiveness. Accessed January 1, 2010.
59. McDonagh M, Peterson K, Thakurta SG, Dana T(2007)DrugClassReviewon Fixed Dose Combination Drug Products for the Treatment of Type 2 Diabetes and Hyperlipidemia. Available: http://www.ohsu.edu/drugeffectiveness/ reports/final.cfm. Accessed January 1, 2010.
60. Norris SL, Lee NJ, Severance S, Thakurta S (2008) Drug class review on newer drugs for the treatment of diabetes mellitus. Available: http://www.ohsu.edu/ drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
61. Hansen RA, Gartlehner G, Lohr KN, Carson S, Carey T (2006) Drug Class Review on Inhaled Corticosteroids. Final Report Update 1. Available: http://derp.ohsu.edu/final/ICS%20Final%20Report%20Annual%20Update%201_ JAN_06.pdf. Accessed January 1, 2010.
62. Carson S, McDonagh M, Thakurta S, Yen P (2008) Drug class review: Insomnia. Available: http://www.ohsu.edu/drugeffectiveness/reports/final. cfm. Accessed January 1, 2010.
63. Chou R, Carson S, Chan BKS, Care B (2007)DrugClass Reviewon Pegylated Interferons for Hepatitis C. Available: http://www.ohsu.edu/drugeffectiveness/ reports/final.cfm. Accessed January 1, 2010.
64. McDonagh M, Dana T, Chan BKS, Thakurta S, Gibler A (2007) Drug Class Review on Disease-modifying drugs for Multiple Sclerosis. Final Report. Available: http://derp.ohsu.edu/final/MS Drugs_Final_Report_original.pdf. Accessed January 1, 2010.
65. Selover D, Dana T, Smith C, Peterson K (2008) Drug class review on nasal corticosteroids. Update #1 final report. Available: http://derp.ohsu.edu/final/NCS_%20Final_%20Report_Update%201_Unshaded_OCT_08.pdf. Accessed January 1, 2010.
66. Chou R, Norris S, Carson S, Chan BKS (2007) Drug Class Review on Drugs for Neuropathic Pain. Available: http://www.ohsu.edu/drugeffectiveness/ reports/final.cfm. Accessed January 1, 2010.
67. Chou R, Carson S (2008) Drug class review on long-acting opioid analgesics. Available: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
68. Chandler C, Chou R, Helfand M (2005) Drug Class Review on Oral Hypoglycemics. Final Report. Available: http://derp.ohsu.edu/final/OH_Final_ Report_Update%202.pdf. Accessed January 1, 2010.
69. McDonagh M, Selover D, Santa J, Thakurta S (2009) Drug class review: Agents for overactive bladder. Update 4. Available: http://www.ohsu.edu/ drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
70. McDonagh MS, Carson S, Thakurta S (2009) Drug class review: Proton pump inhibitors. Update 5. Available: http://www.ohsu.edu/drugeffectiveness/ reports/final.cfm. Accessed January 1, 2010.
71. Chou R, Peterson K (2005) Drug Class Review on Skeletal Muscle Relaxants. Final Report. Avialable: http://derp.ohsu.edu/final/SMR_Final_Report_Update%202. pdf. Accessed January 1, 2010.
72. Smith MEB, Lee NJ, Haney E, Carson S (2009) Drug class review: HMG-CoA reductase inhibitors (statins). Update 5. Available: http://www.ohsu.edu/ drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
73. Gartlehner G, Thieda P, Morgan LC, Thaler K, Hansen RA, et al. (2009) Drug class review: Targeted immune modulators. Update 2 final report. Available: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
74. Norris SL, Carson S (2008) Drug class review: Thiazolidinediones. Available: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
75. Lee NJ, McDonagh MS, Peterson K, Chan B, Thakurta S (2008) Drug class review: Topical calcineurin inhibitors. Original report. Available: http://www. ohsu.edu/drugeffectiveness/reports/final.cfm. [Accessed January 1, 2010].
76. Helfand M, Peterson K (2009) Drug class review: Triptans. Update 4. Available: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. Accessed January 1, 2010.
77. Schneider LS, Anand R, Farlow MR (1998) Systematic review ofthe efficacy of rivastigmine for patients with Alzheimer's disease. International Journal of Geriatric Psychopharmacology 1(Suppl 1): S26-34.
78. Trenkwalder P, Elmfeldt D, Hofman A, Lithell H, Olofsson B, et al. (2005) The Study on COgnition and Prognosis in the Elderly (SCOPE)-major CV events and stroke in subgroups of patients. Blood Press 14: 31-37.
79. Clayton AH, Stewart RS, Fayyad R, Clary CM (2006) Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies. Arch Womens Ment Health 9: 151-157.
80. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, et al. (2002) Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 51: 253-260.
81. Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, et al. (2003) Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28: 1374-1382.
82. Del Favero A, Roila F, M T (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. Ann Oncol 6: 805-810.
83. Hass WK, Easton JD, Adams HP Jr., Pryse-Phillips W, Molony BA, et al. (1989) A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention ofstroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl JMed 321: 501-507.
84. Anonymous (1997) European Stroke Prevention Study 2. Efficacy and safety data JNeurol Sci 151 Suppl: S1-77.
85. Pelham WE, Jr., Walker JL, Sturges J, Hoza J(1989) Comparative effects of methylphenidate on ADD girls and ADD boys. J Am Acad Child Adolesc Psychiatry 28: 773-776.
86. Barkley RA (1989) Hyperactive girls and boys: stimulant drug effects on mother-child interactions. J Child Psychol Psychiatry 30: 379-390.
87. Sonuga-Barke EJ, Coghill D, Markowitz JS, Swanson JM, Vandenberghe M, et al. (2007) Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. J Am Acad Child Adolesc Psychiatry 46: 701-710.
88. Center for Drug Evaluation and Research (2007) Medical Review: NRP104 (lisdexamphetamine dimesylate) NDA #21-977.
89. Sharp WS, Walter JM, Marsh WL, Ritchie GF, Hamburger SD, et al. (1999) ADHD in girls: clinical comparability of a research sample. JAm Acad Child Adolesc Psychiatry 38: 40-47.
90. Robison RJ, Reimherr FW, Marchant BK, Faraone SV, Adler LA, et al. (2008) Gender differences in 2 clinical trials of adults with attention-deficit/ hyperactivity disorder: a retrospective data analysis. J Clin Psychiatry 69: 213-221.
91. Hirschfeld RM, Keck PE, Jr., Kramer M, Karcher K, Canuso C, et al. (2004) Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 161: 1057-1065.
92. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, et al. (2004) Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br JPsychiatry 184: 337-345.
93. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, et al. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J26: 215-225.
94. Hunninghake DB, McGovern ME, Koren M, Brazg R, Murdock D, et al. (2003) A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 26: 112-118.
95. Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D (2002) Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 4: 368-375.
96. Center for Drug Evaluation and Research (2007) Metaglip Medical;Review.
97. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, et al. (2008) Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 79: 291-298.
98. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, et al. (2006) Efficacy and safety ofthe dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49: 2564-2571.
99. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, et al. (2008) Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 24: 537-550.
100. Scott R, Loeys T, Davies MJ, Engel SS (2008) Efficacy and safety ofsitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 10: 959-969.
101. Michel MC, Schneider T, Krege S, Goepel M (2002)Does gender or age affect the efficacy and safety of tolterodine? JUrol 168: 1027-1031.
102. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, et al. (2000) Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 14: 1249-1258.
103. MRC/BHF Heart Protection Study Collaborative Group (1999) MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 20: 725-741.
104. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study ofcholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016.
105. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, et al. (2007) Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 115: 700-707.
106. Davidson MH, Stein EA, Hunninghake DB, Ose L, Dujovne CA, et al. (2000) Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis 10: 253-262.
107. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, et al. (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47: 495-499.
108. Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG (2006) Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. J Affect Disord 94: 183-189.
109. Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z (2007) Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 51: 1054-1064; discussion 1064.
110. Layton D, Pearce GL, Shakir SA(2001) Safety profile oftolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf 24: 703-713.
111. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, BellNE, et al. (1999) Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 13: 179-186.
112. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, et al. (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189-194.